Contributions
Type: Publication Only
Background
The diagnosis of MDS can be difficult, especially in the absence of markers of clonality. Flow cytometry (FCM) has tried to be a useful tool but the methods described so far are poorly standardized and time-consuming.
Aims
Recently, a study has shown that a reduced expression of CD38 in the CD34 + BM cells below a threshold value diagnosed low-grade MDS with high sensitivity and specificity, (Goardon et al, Haematologica, 2009, 94:. 1160-1163 ). Our aim was to test the effectiveness of this method.
Methods
We analyzed 140 BM samples sent to our laboratory between 2012-2015 with suspected MDS. The samples were processed within 24 hours of aspiration and were labeled with an antibody panel that included CD45-FITC, CD34-PE-Cy5 CD38 PE, CD10 PE-Cy7, CD117-APC and CD19-APCCy7. A sufficient number of nucleated cells was acquired on a FACSCanto (Becston Dickinson) flow cytometer and CD38 expression was analyzed in CD34 + myeloid and lymphoid blasts. The expression of CD38 was quantified as a ratio as the MFI of CD38 on CD34 + cells divided by the MFI of isotype control staining . The result was considered pathological below the threshold value described in the study (CD38 IMFR <110)
Results
Of the total of 140 patients, 71 patients were diagnosed with MDS using current WHO criteria (2008): 39 RCDM, 7 RCUD, 2 AR, 10 CMML, 3 RAEB-1, 7 RAEB-2, 1 RARS,1 5q-, 1 MDS / MPD. In them, the ratio CD38 IMFR gave altered in 46 (64.5%). (Media 95.2, range 10.3 - 314.1). 69 patients did not meet criteria for SMD, of which 61 (88.4% patients) had a normal ratio (mean 145.9, range: 63.8 - 808.8).
In our case, the test gave a sensitivity of 64.5% and a specificity of 88.4% in the diagnosis of MDS.
Summary
Our results confirm that CD38 expression is reduced in CD34 + cells from MDS patients and may be helpful in the diagnosis of low-grade MDS.
Type: Publication Only
Background
The diagnosis of MDS can be difficult, especially in the absence of markers of clonality. Flow cytometry (FCM) has tried to be a useful tool but the methods described so far are poorly standardized and time-consuming.
Aims
Recently, a study has shown that a reduced expression of CD38 in the CD34 + BM cells below a threshold value diagnosed low-grade MDS with high sensitivity and specificity, (Goardon et al, Haematologica, 2009, 94:. 1160-1163 ). Our aim was to test the effectiveness of this method.
Methods
We analyzed 140 BM samples sent to our laboratory between 2012-2015 with suspected MDS. The samples were processed within 24 hours of aspiration and were labeled with an antibody panel that included CD45-FITC, CD34-PE-Cy5 CD38 PE, CD10 PE-Cy7, CD117-APC and CD19-APCCy7. A sufficient number of nucleated cells was acquired on a FACSCanto (Becston Dickinson) flow cytometer and CD38 expression was analyzed in CD34 + myeloid and lymphoid blasts. The expression of CD38 was quantified as a ratio as the MFI of CD38 on CD34 + cells divided by the MFI of isotype control staining . The result was considered pathological below the threshold value described in the study (CD38 IMFR <110)
Results
Of the total of 140 patients, 71 patients were diagnosed with MDS using current WHO criteria (2008): 39 RCDM, 7 RCUD, 2 AR, 10 CMML, 3 RAEB-1, 7 RAEB-2, 1 RARS,1 5q-, 1 MDS / MPD. In them, the ratio CD38 IMFR gave altered in 46 (64.5%). (Media 95.2, range 10.3 - 314.1). 69 patients did not meet criteria for SMD, of which 61 (88.4% patients) had a normal ratio (mean 145.9, range: 63.8 - 808.8).
In our case, the test gave a sensitivity of 64.5% and a specificity of 88.4% in the diagnosis of MDS.
Summary
Our results confirm that CD38 expression is reduced in CD34 + cells from MDS patients and may be helpful in the diagnosis of low-grade MDS.